JUNSHIGH SIGNALRISK10-K

JUNS has undergone a fundamental business transformation, abandoning its clinical-stage resveratrol drug development program in favor of a new pharmaceutical licensing model while facing substantial doubt about its ability to continue as a going concern.

The company has completely pivoted away from its proprietary JOTROL resveratrol platform targeting neuroinflammation and rare diseases, replacing it with dependence on an exclusive worldwide license agreement with Aquanova for the Nugevia brand. Management and auditors have expressed substantial doubt about the company's ability to continue operations, while new convertible debt arrangements create additional financial pressure and potential dilution risks.

Comparing 2026-04-01 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a deteriorating cash position with operating cash outflows increasing meaningfully from $3.9M to $5.4M year-over-year. Total assets declined modestly by about 10% to $5.6M, reflecting the ongoing cash burn without meaningful revenue generation. The worsening cash flow dynamics, combined with the going concern qualification and dependence on potentially dilutive financing arrangements, signal significant financial stress for this early-stage company.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-38.4%
-$3.9M→-$5.4M

Operating cash flow fell 38.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
-10.3%
$6.2M→$5.6M

Total assets contracted 10.3% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-28
ADDED
As of March 31, 2026, there were 36,281,252 shares of common stock, par value $ 0.0001 per share, of the registrant issued and outstanding.
These risks and uncertainties include, but are not limited to, the following risks, uncertainties and other factors: Our substantial amount of indebtedness associated with the convertible promissory notes issued in connection with the Standby Equity Purchase Agreement may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants and make payments on our indebtedness.
Low trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase Agreement to pay down the convertible promissory notes.
We have not generated meaningful revenue from product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future; Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.
Our business and future prospects with the Nugevia brand and our pharmaceutical products are significantly dependent on our exclusive, worldwide license agreement with Aquanova.
+7 more — sign up free →
REMOVED
(the Company, we or us ) is a clinical stage research and development company.
We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation.
Our platform product, JOTROL, an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases.
In the larger disease areas, we are primarily targeting Parkinson s Disease and Mild Cognitive Impairment/early Alzheimer s disease.
Business Overview The Company s platform product, JOTROL, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →